Entries by Thomas Gabrielczyk

European dynamics in AMR

Around 130 antibiotics experts joined the 10th Berlin Conference on 24th February to highlight high dynamics of European AMR activities. 

Funding: ENABLE goes pre-clinical

Several promising antibiotic candidates, developed by ENABLE and its partners, are rapidly approaching the pre-clinical development stage. The European consortium is now seeking new partners to proceed with non-clinical studies.

Kick off for BaseLaunch accelerator

BaseLaunch, a new life sciences accelerator in Basel, has been kicked off. Its mission: to bring the most promising healthcare projects and ventures to Europe’s leading life sciences hub.

Roche extends antibiotics collaboration

While governments worldwide discuss to pay premiums to pharma companies offering novel antibiotics that fight multiresistant pathogens, Roche has extended  its discovery deal with British Discuva Ltd.

Bioplastics market growth drops

Growth of the bioplastics market in the EU is being hampered by lack of political support. According to market analysis from nova-institute, production capacity for bio-based polymers in 2016 dropped by 6% compared to previous years.

Roche combo doubles RCC survival vs sunitinib

A combination therapy of Roche’s checkpoint inhibitor atezolizumab plus its VEGF blocker bevacizumab doubles median progression-free survival (PFS) compared to sunitinib, the standard care in renal cell carcinoma (RCC).

BioMedPartners raise CHF75m fund

Basel-based BioMedPartners announes the first round of BioMedInvest III, its third equity venture capital fund at CHF75m. Up to 16 private Swiss, German and EU early-to-midstage ventures might be selected in the first closing by Q1/2018.

Germany to allow GMOs without labelling

While GMO opponents are protesting, German Research Minister Johanna Wanka has recommended to rely on modern genetic engineering methods such as genome editing to develop the next generation of crops.